Podcasts about relapsing multiple sclerosis

Last week, at the American Academy of Neurology annual meeting, Dr. Amit Bar-Or received the John Dystel Prize for Multiple Sclerosis Research for his multiple achievements that have advanced our knowledge of neuroimmunology, precision medicine, and biomarkers in MS. We talked with Dr. Bar-Or about how some of the latest discoveries in MS research would impact patient care.   Tolebrutinib, an investigational disease-modifying therapy, is currently making its way through the FDA's regulatory process. Last week, the results of the Phase 3 clinical trials for Tolebrutinib were published, and we're sharing the details. We'll also tell you about MindGlide, an AI-powered tool for analyzing MRI scans that will significantly reduce MRI exam times. We're talking about the results of the Phase 3 clinical trial for high-dose Ocrevus. And we'll tell you about a cell therapy that doesn't use stem cells that successfully repaired myelin in the mouse model of MS -- twice!  We have a lot to talk about! Are you ready for RealTalk MS??! Congratulations to Dr. Stephen Hauser and Dr. Alberto Ascherio  :22 This Week: The impact of breakthrough MS research on MS care  2:17 Results of the phase 3 clinical trials for Tolebrutinib have been published  3:07 An AI-powered tool for analyzing MRI scans will significantly reduce MRI exam times for patients  4:21 Results of the phase 3 clinical trial for high-dose Ocrevus  8:13 A cell therapy that doesn't use stem cells has successfully repaired myelin in the mouse model of MS -- twice!  10:14 Dystel Prize winner Dr. Amit Bar-Or discusses how some of the latest discoveries in MS  research will impact MS care  12:39 Share this episode  22:36 Have you downloaded the free RealTalk MS app?  22:56 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/397 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com Become an MS Activist Web: https://nationalmssociety.org/advocacy Email: msactivist@nmss.org RealTalk MS Episode 310: The Face Laughs While The Brain Cries: The Education of a Doctor with Dr. Stephen Hauser https://realtalkms.com/310 RealTalk MS ECTRIMS Extra: Results from the Phase 3 Clinical Trial for Tolebrutinib and Relapsing-Remitting MS with Dr. Jiwon Oh https://realtalkms.com/ectrims244 VIDEO: RealTalk MS ECTRIMS Extra: Results from the Phase 3 Clinical Trial for Tolebrutinib and Relapsing-Remitting MS with Dr. Jiwon Oh https://youtu.be/zcBmAHRTotA VIDEO: RealTalk MS ECTRIMS Extra: Results from the Phase 3 Clinical Trial for Tolebrutinib and Nonrelapsing Secondary Progressive MS with Dr. Robert Fox https://youtu.be/tJQ93qdlXrU STUDY: Tolebrutinib Versus Teriflunomide in Relapsing Multiple Sclerosis https://nejm.org/doi/full/10.1056/NEJMoa2415985 STUDY: Tolebrutinib in Nonrelapsing Secondary Progressive Multiple Sclerosis https://nejm.org/doi/full/10.1056/NEJMoa2415988 Enabling New Insights from Old Scans By Repurposing Clinical MRI Archives for Multiple Sclerosis Research https://www.nature.com/articles/s41467-025-58274-8 Fibroblast Technology https://fibrobiologics.com/technology/#cnsms Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 398 Guests: Dr. Amit Bar-Or Privacy Policy

MedLink Neurology Podcast is delighted to feature selected episodes from BrainWaves, courtesy of James E Siegler MD, its originator and host. BrainWaves is an academic audio podcast whose mission is to educate medical providers through clinical cases and topical reviews in neurology, medicine, and the humanities, and episodes originally aired from 2016 to 2021. Originally released: July 5, 2018 In 2017, neuroimmunology experts revised the criteria with which we diagnose multiple sclerosis. They encouraged more aggressive treatment, and now they have introduced novel therapeutic agents into our pharmacologic armamentarium. Dr. Christopher Perrone explains how these newer agents work and how effective they are in patients with demyelinating disease. Produced by James E Siegler. Music by Steve Combs, Pachyderm, and Lee Rosevere. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision-making. REFERENCES Hauser SL, Bar-Or A, Comi G, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med 2017;376(3):221-34. PMID 28002679Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358(7):676-88. PMID 18272891Hemmer B, Nessler S, Zhou D, Kieseier B, Hartung HP. Immunopathogenesis and immunotherapy of multiple sclerosis. Nat Clin Pract Neurol 2006;2(4):201-11. PMID 16932551Maloney DG, Grillo-López AJ, White CA, et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997;90(6):2188-95. PMID 9310469Montalban X, Hauser SL, Kappos L, et al. Ocrelizumab versus placebo in primary progressive multiple sclerosis. N Engl J Med 2017;376(3):209-20. PMID 28002688Selter RC, Hemmer B. Update on immunopathogenesis and immunotherapy in multiple sclerosis. Immunotargets Ther 2013;2:21-30. PMID 27471685  We believe that the principles expressed or implied in the podcast remain valid, but certain details may be superseded by evolving knowledge since the episode's original release date.

Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world. French drugmaker Sanofi has announced positive results from a Phase II trial of its experimental drug frexalimab in relapsing multiple sclerosis (MS). The trial, published in the New England Journal of Medicine, showed that frexalimab significantly slowed disease activity in patients with relapsing MS. The drug targets a protein called CD40L, which is involved in the activation of immune cells that attack the protective covering of nerve fibers in patients with MS. Sanofi plans to continue clinical testing of frexalimab and aims for peak annual sales of $5 billion for the drug.In other news, biopharma companies Catalent, Aurinia, and Sandoz have recently announced staff cuts. Biospace is tracking these layoffs and providing updates on the latest industry developments.Moving on to funding news, biotech company Freenome has raised $254 million in a fundraising round led by Roche. Freenome is developing blood-based tests for cancer detection and aims to advance its tests as pivotal readouts approach. Another biotech company, Firefly Bio, has emerged from stealth mode with $94 million in Series A funding. Firefly Bio is focused on developing antibody-drug conjugates and protein degraders for targeted cancer therapies.Lastly, Bristol Myers Squibb is leading the future of protein degradation with its three-pronged approach to developing targeted protein degraders. The company aims to design next-generation degraders that can attack disease targets with precision and agility.These developments highlight the progress being made in the biopharma industry in areas such as multiple sclerosis treatment, cancer detection, targeted cancer therapies, and protein degradation.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, we spoke with a variety of specialists in neurology who presented research and gave talks at the 75th American Academy of Neurology Annual Meeting, held April 22-27, 2023, in Boston, Massachusetts. Those included in this week's episode, in order of appearance, are: Michael H. Barnett, MBBS, PhD, FRACP, a consultant neurologist at Royal Prince Alfred Hospital (RPAH) Sydney, director of the RPAH MS Clinic and the MS Clinical Trials Unit at the Brain and Mind Centre; codirector of the MS Research Australia Brain Bank; and a senior professor at the University of Sydney. Nancy R. Foldvary-Schaefer, DO, FAAN, the director of the Sleep Disorders Center and staff in the Epilepsy Center at Cleveland Clinic, and a professor of medicine at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University. Sean J. Pittock, MD, the director of the Center for Multiple Sclerosis and Autoimmune Neurology and director of the Neuroimmunology Research Laboratory at Mayo Clinic. Katherine W. Turk, MD, a neurologist at Boston VA Memory Disorders Clinic, principal investigator and codirector of the Center for Translational Cognitive Neuroscience lab (CTCN) at VA Boston; and assistant professor of neurology and coleader of the Outreach, Recruitment and Engagement core of the Alzheimer's Disease Research Center at Boston University. Erika U. Augustine, MD, MS, the associate chief science officer and director of the Clinical Trials Unit at the Kennedy Krieger Institute. Jeffrey M. Statland, MD, a neuromuscular disease specialist and professor of neurology at the University of Kansas Medical Center. Chian-Chun Chiang, MD, a stroke and migraine specialist and assistant professor of neurology at Mayo Clinic. Want more from the 75th American Academy of Neurology Annual Meeting? Click here for all of NeurologyLive®'s coverage of AAN 2023. Episode Breakdown: 1:10 – Barnett on the topline findings for CNM-Au8 from the VISIONARY-MS clinical trial. 8:35 – Foldvary-Schaefer on the understanding of the relationship between epilepsy and sleep. 13:25 – Pittock on the latest data on ravulizumab from the CHAMPION-NMOSD trial. 19:00 – Turk on the landscape of diagnosis and treatment for mild cognitive impairment, and how to improve the process. 22:00 – Augustine on Dr. Sidney Carter and the current paradigm of care in child neurology. 27:15 – Statland on the findings for ataluren in nonsense mutation Duchenne muscular dystrophy from Study 041. 34:05 – Chiang on the takeaways from a big data analysis of 25 therapies for acute migraine management. This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com. Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com. REFERENCES 1. Barnett MH. VISIONARY-MS Top-line Results: A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo-controlled Study to Assess the Safety and Efficacy of CNM-Au8, a Catalytically Active Gold Nanocrystal Suspension in Relapsing Multiple Sclerosis. Presented at: AAN Annual Meeting; April 22-27, 2023; Boston, MA. 2. Foldvary-Schaefer NR. Diagnostic Testing: Beyond the MSLT. Presented at: AAN Annual Meeting; April 22-27, 2023; Boston, MA. 3. Pittock SJ. Efficacy and safety of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: outcomes from the phase 3 CHAMPION-NMOSD trial. Presented at: AAN Annual Meeting; April 22-27, 2023; Boston, MA. 4. Statland JM. Safety and Efficacy of Ataluren in nmDMD Patients from Study 041, a Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial. Presented at: AAN Annual Meeting; April 22-27, 2023; Boston, MA. 5. Chiang CC. Simultaneous Comparisons of 25 Acute Migraine Medications: A Big Data Analysis of 10 Million Patient Self-Reported Treatment Records From A Migraine Smartphone Application. Presented at: AAN Annual Meeting; April 22-27, 2023; Boston, MA.

Please visit answersincme.com/BAV860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neurology discusses Bruton's tyrosine kinase (BTK) inhibitors in relapsing multiple sclerosis (MS). Upon completion of this activity, participants should be better able to: Recognize the biologic rationale for therapeutically targeting BTK in MS; Describe the clinical impact of late-stage emerging BTK inhibitors in relapsing MS; and Outline clinical considerations for the future use of BTK inhibitors in the management of relapsing MS.

Every episode of RealTalk MS features updates and reports about emerging science. And, as you listen, some of you may wonder, 'When will these scientific achievements benefit me? When will these breakthroughs and advancements make their way from the laboratory workbench to the clinic?'   That's exactly what the panel of MS experts who comprise the International Advisory Committee on Clinical Trials in MS are proposing in a new framework that leverages what scientists are continuing to learn and re-defines how we talk about MS, research MS, diagnose MS, and treat MS.  The new framework being recommended by the committee is broadly outlined in a paper that was published about 8 weeks ago. Joining me to discuss what this proposed framework is all about is the paper's lead author, Professor Tanja Kuhlmann. We're also talking about the new high-efficacy disease-modifying therapy that received its FDA approval last week. We're sharing the details behind the FDA's approval of a Phase 3 clinical trial for Masitinib, an investigational therapy for treating progressive MS. We'll tell you about Abata Therapeutics' first T-cell treatment candidate for treating progressive MS. And you'll hear about the results of a study that compared the outcome of treating people living with secondary progressive MS with autologous hematopoietic stem cell transplantation (aHSCT) versus treatment by disease-modifying therapies. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: Experts recommend a new framework for researching, diagnosing, and treating MS  :22 FDA approves Ublituximab (Briumvi), an anti-cd20 disease-modifying therapy  1:12 FDA approves Phase 3 clinical trial for Masitinib as a treatment for progressive MS  4:35 Abata Therapeutics announces its first T-cell therapy candidate to treat progressive MS  7:20 Study shows aHSCT more effective than DMTs in treating secondary progressive MS  10:14 Professor Tanja Kuhlmann discusses a new framework for researching, diagnosing, and treating MS  13:51 Share this episode  26:37 Have you downloaded the free RealTalk MS app?  26:57 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/279 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com STUDY: Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis https://nejm.org/doi/full/10.1056/NEJMoa2201904 AB Science https://ab-science.com RealTalk MS Episode 205: A Potentially Transformational Therapy for Progressive MS with Samantha Singer and Dr. Richard Ransohoff https://realtalkms.com/205 STUDY: Hematopoietic Stem Cell Transplantation in People with Active Secondary Progressive MS https://n.neurology.org/content/early/2022/12/21/WNL.0000000000206750 Take the iConquer MS Caregiver Survey https://realtalkms.com/caregiver Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 279 Guest: Professor Tanja Kuhlmann Tags: MS, MultipleSclerosis, MSResearch, MSSociety, RealTalkMS Privacy Policy

Living with MS comes with its own set of sometimes significant challenges.  But being in the dark, unaware of the noteworthy and remarkable advances being made in MS research is one challenge that we're learning to overcome.  Sharon Roman is a patient-partner and writer for the British Medical Journal Group. Sharon lives with MS and she also writes a blog called Tremlett's MS Research Explained. The blog features plain-English posts detailing the research being done by Professor Helen Tremlett and her team. Professor Tremlett is the Canada Research Chair in Neuroepidemiology and Multiple Sclerosis at the University of British Columbia. Sharon joins me to talk about Professor Tremlett's pioneering research on the prodromal phase of MS, and to discuss why it's important to make MS research accessible and understandable to everyone in the MS community. We're also sharing study results that show the key to reducing MS fatigue could be a trip to the gym. We'll tell you about a study that measured improvements in physical disability, fatigue, and health-related quality of life among people with MS after they received stem cell therapy. We'll tell you about the significant differences in the gut microbiome of people living with MS and what that might mean for potential new treatments. We'll tell you about a study that discovered an interesting difference in immune cells among people living with MS. And we'll explain the riddle this poses for scientists. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: The importance of making MS research accessible to people affected by MS  :22 A study shows that high-intensity resistance training improves MS fatigue  2:44 A study measures the long-lasting benefits of aHSCT for people living with MS   6:31 A study identifies differences in specific bacteria levels in the gut microbiome of people living with MS  9:59 A study reveals differences in immune cells among people living with MS  13:22 Sharon Roman discusses the importance of making MS research accessible to people affected by MS  18:43 Share this episode  32:04 Download the RealTalk MS app for your iOS or Android device   32:24 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/265 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com National MS Society COVID-19 Vaccine Guidance for People Living with MS https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance Tremlett's MS Research Explained https://tremlettsmsresearchexplained.wordpress.com STUDY: High-Intensity Resistance Training in People with Multiple Sclerosis Experiencing Fatigue: A Randomised Controlled Study https://msard-journal.com/article/S2211-0348(22)00613-7/fulltext STUDY: Impact of Autologous HSCT on the Quality of Life and Fatigue in Patients with Relapsing Multiple Sclerosis https://www.nature.com/articles/s41598-022-19748-7 National MS Society: aHSCT and MShttps://nationalmssociety.org/Treating-MS/aHSCT STUDY: Gut Microbiome of Multiple Sclerosis Patients and Paired Household Controls Reveal Associations with Disease Risk and Course https://cell.com/cell/fulltext/S0092-8674(22)01115-1 STUDY: Broader Epstein-Barr Virus-Specific T Cell Receptor Repertoire in Patients with Multiple Sclerosis https://rupress.org/jem/article/219/11/e20220650/231431/Broader-Epstein-Barr-virus-specific-T-cell Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 265 Guest: Sharon Roman Tags: MS, MultipleSclerosis, MSResearch, MSSociety, RealTalkMS Privacy Policy

When you're living with MS, even the most mundane daily tasks can sometimes be challenging. There are days when opening a door, taking things out of a drawer or a cupboard, or picking something up from the floor can all seem out of reach. Those just happen to be some of the many tasks that a service dog can help you with. This week, attorney Trevor Hardy joins me to talk about the impact that his service dog, Tristan, has had on his life.  We're also reviewing what you need to know about monkeypox and MS. We'll share the results from a Phase 3 clinical trial for Ublituximab, an investigational anti-cd20 therapy for MS. We'll talk with Dr. Roberto-Alfonso Dunn about the results of a study that he recently headed up at Tisch Multiple Sclerosis Research Center. And we'll share results from a study that attempted to identify specific factors at the time of diagnosis that could be predictive of future physical and mental health-related quality of life. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: Study results and service dogs  :23 Monkeypox and MS: What you need to know  1:13 Results from the Phase 3 clinical trial for Ublituximab  6:03 Study results offer potentially encouraging news for people with MS on b-cell depleting therapies  8:58 Clues at the time of diagnosis are shown to be predictive of future physical and mental health-related quality of life  17:20 Trevor Hardy discusses how his service dog, Tristan, has changed his life  24:33 Share this episode  36:22 Download the RealTalk MS app for your iOS or Android device   36:42 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/261 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com National MS Society COVID-19 Vaccine Guidance for People Living with MS https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance Monkeypox and MS: What You Need to Know https://www.nationalmssociety.org/About-the-Society/News/Monkeypox CDC: Monkeypox Vaccines https://www.cdc.gov/poxvirus/monkeypox/vaccines.html STUDY: Ublituximab versus Teriflunomide in Relapsing Multiple Sclerosis https://www.nejm.org/doi/full/10.1056/NEJMoa22019094 STUDY: Physical and Mental Health-Related Quality of Life Trajectories Among People with Multiple Sclerosishttps://n.neurology.org/content/early/2022/08/10/WNL.000000000200931 Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 261 Guest: Dr. Roberto-Alfonso Dunn and Trevor Hardy Tags: MS, MultipleSclerosis, MSResearch, MSSociety, RealTalkMS Privacy Policy  

Women are roughly 3 times more likely to develop MS compared to men. But when men develop MS, they're more likely to experience a more aggressive disease course. Men are more likely to experience motor problems, loss of coordination and balance, and cognitive difficulties. When they experience a relapse, men are more likely to see their exacerbated symptoms continue, even during times of remission. Given these evidence-based observations, it seems sadly ironic that, as they develop MS symptoms, men are less likely to seek medical care or even a diagnosis. Dr. Robert Shin returns to the podcast to demystify some of the riddles surrounding men and MS. Dr. Shin is a Professor in the Department of Neurology at MedStar Georgetown University Hospital, and the Director of the Georgetown Multiple Sclerosis and Neuroimmunology Center. We're also sharing the registration details for the National MS Society's webcast, What Does the New Drug Pricing Law Mean to You?. The webcast takes place this Thursday, and you won't want to miss it. We'll tell you about a study that may have identified an imaging biomarker that can predict future MS progression. (And we'll explain why that can make a huge difference in your MS treatment plan) We'll share some discouraging news about the availability of Evusheld in the U.K. We'll point you toward Elizabeth Jameson's Washington Post editorial that explains how learning to swear can be therapeutic for someone living with progressive MS. And we'll share results from a Cleveland Clinic study that shows how a man's own definition of masculinity can get in the way of his MS treatment. We have a lot to talk about! Are you ready for RealTalk MS??! This Week: MS and Men  :22 Find out how and when the Inflation Reduction Act will impact the cost of your prescription drugs  1:41 Study demonstrates that thinning of retinal layers predicts future MS disability  2:35 U.K. opts not to buy Evusheld  5:17 Elizabeth Jameson learns the value of a well-intentioned F-bomb  6:35 Study shows how masculine ideals drive healthcare decisions for men with MS  8:39 Dr. Robert Shin discusses the specifics associated with Men and MS  12:52 Share this episode  30:56 Download the RealTalk MS app for your iOS or Android device   31:16 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/260 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jon@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com National MS Society COVID-19 Vaccine Guidance for People Living with MS https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance Registration for National MS Society Webcast: What Does the New Drug Pricing Law Mean to You? https://nmss.zoom.us/webinar/register/WN_auRCXBi2TGCgzHeV1CWMkw STUDY: Retinal Thinning After Optic Neuritis is Associated with Future Relapse Remission in Relapsing Multiple Sclerosis https://neurology.org/content/early/2022/08/01/WNL.0000000000200970 Elizabeth Jameson in the Washington Post: How I Learned that Swearing Can Be Good for the Soul https://wapo.st/3vpRJeo STUDY: Effects of Conformity to Masculine Norms and Coping on Health Behaviors in Men with Multiple Sclerosishttps://doi.org/10.7224/1537-2073.2020-116 Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 260 Guest: Dr. Robert Shin Tags: MS, MultipleSclerosis, MSResearch, MSSociety, RealTalkMS Privacy Policy  

Go online to PeerView.com/REK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For individuals with multiple sclerosis (MS), “invisible symptoms” that include cognitive changes and fatigue exacerbate the burden of disease. Emerging evidence indicates that in addition to providing high efficacy, safety, tolerability, and patient convenience, sphingosine 1-phosphate receptor (S1PR) modulators may yield important benefits related to loss of cortical gray matter and whole brain volume, addressing cognition as well as multiple other aspects of MS. At a recent live event, our expert faculty reviewed the mechanism of action of S1PR modulators and their important role in MS care, with a focus on the clinically relevant distinctions among members of this class—from first-generation fingolimod to the more recently introduced siponimod, ozanimod, and ponesimod. The faculty discussed the role of agent-specific characteristics such as relative selectivity and off-target effects in individualized treatment planning—reviewing key trial data on patient outcomes and concluding with a case-based workshop addressing treatment selection, shared decision-making, and COVID-19 vaccination. Upon completion of this activity, participants should be better able to: Discuss the rationale for the modulation of S1P function as a therapeutic approach in multiple sclerosis (MS) in the context of disease pathophysiology; Individualize S1PR modulator therapy for patients with MS based on the latest evidence on safety, efficacy, and the potential impact on physical and cognitive outcomes; and Apply a patient-centered, team-based approach to treatment selection and sequencing in MS based on the patient's disease activity, treatment preferences and goals, and therapeutic options.

Go online to PeerView.com/REK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For individuals with multiple sclerosis (MS), “invisible symptoms” that include cognitive changes and fatigue exacerbate the burden of disease. Emerging evidence indicates that in addition to providing high efficacy, safety, tolerability, and patient convenience, sphingosine 1-phosphate receptor (S1PR) modulators may yield important benefits related to loss of cortical gray matter and whole brain volume, addressing cognition as well as multiple other aspects of MS. At a recent live event, our expert faculty reviewed the mechanism of action of S1PR modulators and their important role in MS care, with a focus on the clinically relevant distinctions among members of this class—from first-generation fingolimod to the more recently introduced siponimod, ozanimod, and ponesimod. The faculty discussed the role of agent-specific characteristics such as relative selectivity and off-target effects in individualized treatment planning—reviewing key trial data on patient outcomes and concluding with a case-based workshop addressing treatment selection, shared decision-making, and COVID-19 vaccination. Upon completion of this activity, participants should be better able to: Discuss the rationale for the modulation of S1P function as a therapeutic approach in multiple sclerosis (MS) in the context of disease pathophysiology; Individualize S1PR modulator therapy for patients with MS based on the latest evidence on safety, efficacy, and the potential impact on physical and cognitive outcomes; and Apply a patient-centered, team-based approach to treatment selection and sequencing in MS based on the patient's disease activity, treatment preferences and goals, and therapeutic options.

Go online to PeerView.com/REK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For individuals with multiple sclerosis (MS), “invisible symptoms” that include cognitive changes and fatigue exacerbate the burden of disease. Emerging evidence indicates that in addition to providing high efficacy, safety, tolerability, and patient convenience, sphingosine 1-phosphate receptor (S1PR) modulators may yield important benefits related to loss of cortical gray matter and whole brain volume, addressing cognition as well as multiple other aspects of MS. At a recent live event, our expert faculty reviewed the mechanism of action of S1PR modulators and their important role in MS care, with a focus on the clinically relevant distinctions among members of this class—from first-generation fingolimod to the more recently introduced siponimod, ozanimod, and ponesimod. The faculty discussed the role of agent-specific characteristics such as relative selectivity and off-target effects in individualized treatment planning—reviewing key trial data on patient outcomes and concluding with a case-based workshop addressing treatment selection, shared decision-making, and COVID-19 vaccination. Upon completion of this activity, participants should be better able to: Discuss the rationale for the modulation of S1P function as a therapeutic approach in multiple sclerosis (MS) in the context of disease pathophysiology; Individualize S1PR modulator therapy for patients with MS based on the latest evidence on safety, efficacy, and the potential impact on physical and cognitive outcomes; and Apply a patient-centered, team-based approach to treatment selection and sequencing in MS based on the patient's disease activity, treatment preferences and goals, and therapeutic options.

Go online to PeerView.com/REK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For individuals with multiple sclerosis (MS), “invisible symptoms” that include cognitive changes and fatigue exacerbate the burden of disease. Emerging evidence indicates that in addition to providing high efficacy, safety, tolerability, and patient convenience, sphingosine 1-phosphate receptor (S1PR) modulators may yield important benefits related to loss of cortical gray matter and whole brain volume, addressing cognition as well as multiple other aspects of MS. At a recent live event, our expert faculty reviewed the mechanism of action of S1PR modulators and their important role in MS care, with a focus on the clinically relevant distinctions among members of this class—from first-generation fingolimod to the more recently introduced siponimod, ozanimod, and ponesimod. The faculty discussed the role of agent-specific characteristics such as relative selectivity and off-target effects in individualized treatment planning—reviewing key trial data on patient outcomes and concluding with a case-based workshop addressing treatment selection, shared decision-making, and COVID-19 vaccination. Upon completion of this activity, participants should be better able to: Discuss the rationale for the modulation of S1P function as a therapeutic approach in multiple sclerosis (MS) in the context of disease pathophysiology; Individualize S1PR modulator therapy for patients with MS based on the latest evidence on safety, efficacy, and the potential impact on physical and cognitive outcomes; and Apply a patient-centered, team-based approach to treatment selection and sequencing in MS based on the patient's disease activity, treatment preferences and goals, and therapeutic options.

Go online to PeerView.com/REK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For individuals with multiple sclerosis (MS), “invisible symptoms” that include cognitive changes and fatigue exacerbate the burden of disease. Emerging evidence indicates that in addition to providing high efficacy, safety, tolerability, and patient convenience, sphingosine 1-phosphate receptor (S1PR) modulators may yield important benefits related to loss of cortical gray matter and whole brain volume, addressing cognition as well as multiple other aspects of MS. At a recent live event, our expert faculty reviewed the mechanism of action of S1PR modulators and their important role in MS care, with a focus on the clinically relevant distinctions among members of this class—from first-generation fingolimod to the more recently introduced siponimod, ozanimod, and ponesimod. The faculty discussed the role of agent-specific characteristics such as relative selectivity and off-target effects in individualized treatment planning—reviewing key trial data on patient outcomes and concluding with a case-based workshop addressing treatment selection, shared decision-making, and COVID-19 vaccination. Upon completion of this activity, participants should be better able to: Discuss the rationale for the modulation of S1P function as a therapeutic approach in multiple sclerosis (MS) in the context of disease pathophysiology; Individualize S1PR modulator therapy for patients with MS based on the latest evidence on safety, efficacy, and the potential impact on physical and cognitive outcomes; and Apply a patient-centered, team-based approach to treatment selection and sequencing in MS based on the patient's disease activity, treatment preferences and goals, and therapeutic options.

Go online to PeerView.com/REK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For individuals with multiple sclerosis (MS), “invisible symptoms” that include cognitive changes and fatigue exacerbate the burden of disease. Emerging evidence indicates that in addition to providing high efficacy, safety, tolerability, and patient convenience, sphingosine 1-phosphate receptor (S1PR) modulators may yield important benefits related to loss of cortical gray matter and whole brain volume, addressing cognition as well as multiple other aspects of MS. At a recent live event, our expert faculty reviewed the mechanism of action of S1PR modulators and their important role in MS care, with a focus on the clinically relevant distinctions among members of this class—from first-generation fingolimod to the more recently introduced siponimod, ozanimod, and ponesimod. The faculty discussed the role of agent-specific characteristics such as relative selectivity and off-target effects in individualized treatment planning—reviewing key trial data on patient outcomes and concluding with a case-based workshop addressing treatment selection, shared decision-making, and COVID-19 vaccination. Upon completion of this activity, participants should be better able to: Discuss the rationale for the modulation of S1P function as a therapeutic approach in multiple sclerosis (MS) in the context of disease pathophysiology; Individualize S1PR modulator therapy for patients with MS based on the latest evidence on safety, efficacy, and the potential impact on physical and cognitive outcomes; and Apply a patient-centered, team-based approach to treatment selection and sequencing in MS based on the patient's disease activity, treatment preferences and goals, and therapeutic options.

Go online to PeerView.com/REK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For individuals with multiple sclerosis (MS), “invisible symptoms” that include cognitive changes and fatigue exacerbate the burden of disease. Emerging evidence indicates that in addition to providing high efficacy, safety, tolerability, and patient convenience, sphingosine 1-phosphate receptor (S1PR) modulators may yield important benefits related to loss of cortical gray matter and whole brain volume, addressing cognition as well as multiple other aspects of MS. At a recent live event, our expert faculty reviewed the mechanism of action of S1PR modulators and their important role in MS care, with a focus on the clinically relevant distinctions among members of this class—from first-generation fingolimod to the more recently introduced siponimod, ozanimod, and ponesimod. The faculty discussed the role of agent-specific characteristics such as relative selectivity and off-target effects in individualized treatment planning—reviewing key trial data on patient outcomes and concluding with a case-based workshop addressing treatment selection, shared decision-making, and COVID-19 vaccination. Upon completion of this activity, participants should be better able to: Discuss the rationale for the modulation of S1P function as a therapeutic approach in multiple sclerosis (MS) in the context of disease pathophysiology; Individualize S1PR modulator therapy for patients with MS based on the latest evidence on safety, efficacy, and the potential impact on physical and cognitive outcomes; and Apply a patient-centered, team-based approach to treatment selection and sequencing in MS based on the patient's disease activity, treatment preferences and goals, and therapeutic options.

Go online to PeerView.com/REK860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. For individuals with multiple sclerosis (MS), “invisible symptoms” that include cognitive changes and fatigue exacerbate the burden of disease. Emerging evidence indicates that in addition to providing high efficacy, safety, tolerability, and patient convenience, sphingosine 1-phosphate receptor (S1PR) modulators may yield important benefits related to loss of cortical gray matter and whole brain volume, addressing cognition as well as multiple other aspects of MS. At a recent live event, our expert faculty reviewed the mechanism of action of S1PR modulators and their important role in MS care, with a focus on the clinically relevant distinctions among members of this class—from first-generation fingolimod to the more recently introduced siponimod, ozanimod, and ponesimod. The faculty discussed the role of agent-specific characteristics such as relative selectivity and off-target effects in individualized treatment planning—reviewing key trial data on patient outcomes and concluding with a case-based workshop addressing treatment selection, shared decision-making, and COVID-19 vaccination. Upon completion of this activity, participants should be better able to: Discuss the rationale for the modulation of S1P function as a therapeutic approach in multiple sclerosis (MS) in the context of disease pathophysiology; Individualize S1PR modulator therapy for patients with MS based on the latest evidence on safety, efficacy, and the potential impact on physical and cognitive outcomes; and Apply a patient-centered, team-based approach to treatment selection and sequencing in MS based on the patient's disease activity, treatment preferences and goals, and therapeutic options.

Beth is an autoimmune disease connoisseur. She's 26 and has spent the past 13 years collecting autoimmune disorders including Aggressive Remitting and Relapsing Multiple Sclerosis (MS). This week she joins the fellas to walk them through her wild and fast diagnosis of MS and how although MS sucks, it doesn't even come close to affecting her as much as her Type I Diabetes does (again, this gal has quite the collection.) From her experience in confusing docs for years to the vast library of medicines she takes, Beth gives us a small glimpse into the life of a Sickgirl. *Join the post-episode conversation over on Discord! https://discord.gg/expeUDN

Beth is an autoimmune disease connoisseur. She's 26 and has spent the past 13 years collecting autoimmune disorders including Aggressive Remitting and Relapsing Multiple Sclerosis (MS). This week she joins the fellas to walk them through her wild and fast diagnosis of MS and how although MS sucks, it doesn't even come close to affecting her as much as her Type I Diabetes does (again, this gal has quite the collection.) From her experience in confusing docs for years to the vast library of medicines she takes, Beth gives us a small glimpse into the life of a Sickgirl. *Join the post-episode conversation over on Discord! https://discord.gg/expeUDN

A decade ago, the International Progressive MS Alliance didn't exist. Today, it can be credited with changing the global conversation about progressive MS research, elevating the progressive MS research agenda and moving the work forward. A few weeks ago, the Alliance announced the details of an ambitious strategic plan that will guide their work over the next 3 years.  Joining me to talk about the new goals that were set by the Alliance, and what that means for people affected by progressive MS, is the Chair of the Alliance's Scientific Steering Committee, Dr. Robert Fox. The MS International Federation conducted a survey and we're wondering whether the responses have raised a larger question? We're also talking about a study that showed how an online mindfulness program significantly improved depression for people living with MS. We're sharing study results that show your nose knows when your DMT is working well for you. We'll also share the details about an exciting undertaking at the University of Colorado that may lead to treating people so that they completely avoid the symptoms of MS. And we'll tell you about a small trial that demonstrated the effectiveness of an experimental stem cell therapy as a potential treatment for progressive MS. We have a lot to talk about! Are you ready for RealTalk MS??! International Progressive MS Alliance unveils a new 3-year strategic plan  :22 Survey results raise a larger question -- How do we share MS research news with people affected by MS???  1:04 Online mindfulness provides significant improvement for managing depression among people with MS    16:14 Using your nose to determine the efficacy of your disease-modifying therapy  8:33 NeuroGenesis cell therapy shows promise as a potential treatment for progressive MS  14:14 Dr. Robert Fox discusses what's next for the International Progressive MS Alliance  17:28 Share this episode  28:07 Have you downloaded the RealTalk MS app?   28:27 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/239 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jonstrum@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com National MS Society COVID-19 Vaccine Guidance for People Living with MS https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance International Progressive MS Alliance https://progressivemsalliance.org STUDY: A Randomized Controlled Trial of a Web-Based Mindfulness Programme for People With MS With and Without a History of Recurrent Depression https://journals.sagepub.com/doi/10.1177/13524585211068002 STUDY: Olfactory Threshold Predicts Treatment Response in Relapsing Multiple Sclerosis https://journals.sagepub.com/doi/10.1177/1354285221079744 STUDY: Effects of Mesenchymal Stem Cell Transplantation on Cerebrospinal Fluid Biomarkers in Progressive MS https://academic.oup.com/stcltm/article/11/1/55/6528889 Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 239 Guests: Dr. Robert Fox Tags: MS, MultipleSclerosis, MSResearch, MSSociety, RealTalkMS Privacy Policy

It's MS Awareness Week and my guest is Marti Hines. Marti is a successful event producer, entrepreneur, film producer, and director. She was diagnosed with MS in 2018, and Marti has been very transparent in sharing the highs and lows of her MS journey on her social channels.  Like so many people living with MS, Marti has an amazing energy and a seemingly endless supply of resilience. You're going to enjoy meeting her.  We're also talking about why increasing diversity in clinical trials is so vital. And we're highlighting the Consensus Statement on Health Equity in Clinical Trials and Real-World Evidence Data Collection that was released by the National MS Society's Corporate Healthcare Roundtable. You'll learn about the Cost Plus Drug Company, billionaire Mark Cuban's effort to disrupt the prescription drug market by offering generic drugs that truly are affordable. And we'll share the results of a study that shows that a keto diet may be beneficial for people living with relapsing MS. We have a lot to talk about! Are you ready for RealTalk MS??! It's MS Awareness Week!  :22 MS Society Corporate Healthcare Roundtable issues a consensus statement on health equity in clinical trials  1:03 Mark Cuban Cost Plus Drug Company is compassionate capitalism in action  5:59 Keto diet shows benefits for people with  relapsing MS  11:18 Marti Hines talks about why sharing her MS journey is important  14:51 Share this episode  26:08 Have a minute? Leave a rating and review for RealTalk MS!   26:28 SHARE THIS EPISODE OF REALTALK MS Just copy this link & paste it into your text or email: https://realtalkms.com/237 ADD YOUR VOICE TO THE CONVERSATION I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts! Email: jonstrum@realtalkms.com Phone: (310) 526-2283 And don't forget to join us in the RealTalk MS Facebook group! LINKS If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com National MS Society COVID-19 Vaccine Guidance for People Living with MS https://www.nationalmssociety.org/coronavirus-covid-19-information/multiple-sclerosis-and-coronavirus/covid-19-vaccine-guidance National MS Society MS Awareness Week https://nationalmssociety.org/msawareness National MS Society Corporate Healthcare Roundtable Consensus Statement on Health Equity in Clinical Trials and Real-World Evidence Data Collection  https://nmsscdn.azureedge.net/NationalMSSociety/media/MSNationalFiles/Documents/Corporate-Healthcare-Roundtable_Consensus-Statement-on-Health-Equity-in-Clinical-Trials-and-Data-Collection-(2).pdf National MS Society Public Policy Conference Replay https://nationalmssociety.org/ppc Mark Cuban Cost Plus Drug Company https://costplusdrugs.com STUDY: Ketogenic Diet as a Strategy for Improved Wellness and Reduced Disability in Relapsing Multiple Sclerosis https://index.mirasmart.com/aan2022/PDFfiles/AAN2022-000622.html Join the RealTalk MS Facebook Group https://facebook.com/groups/realtalkms Download the RealTalk MS App for iOS Devices https://itunes.apple.com/us/app/realtalk-ms/id1436917200 Download the RealTalk MS App for Android Deviceshttps://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk Give RealTalk MS a rating and review http://www.realtalkms.com/review Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com. RealTalk MS Episode 237 Guests: Marti Hines Tags: MS, MSAwareness MultipleSclerosis, MSResearch, MSSociety, RealTalkMS Privacy Policy

Multiple Sclerosis News Today columnist, Jenn Powell discusses how Plegridy and Avonex, may be used in women with relapsing multiple sclerosis who are, or are considering becoming, pregnant. Are you interested in learning more about Multiple Sclerosis? If so, please visit https://multiplesclerosisnewstoday.com/

Antje Bischof, from the University of California, San Fransisco, talks about her research "Accelerated Cord Atrophy Precedes Conversion to Secondary Progressive Disease in Relapsing Multiple Sclerosis," which she presented at ACTRIMS Forum 2019. Read more at

Lauren talks about the power of mirroring in relationships, and how it positively impacts her work as an interviewer and a therapist--mirroring is reflecting back what the other person has shared in order to improve communication. Lauren beautifully describes how she intentionally feel into emotions before and during sessions/interviews as a way to be an even more effective practitioner practitioner/interviewer. We also talk about friendships, and Lauren talks about specific exercises and tools that can be sued with a partner or friend to get closer and learn more about each other. QUOTES-- This emotion is perfect for this moment My goal is to feel everything that arises in me Feeling are superpowers Another name for HSP--A person who gets the texture of life BIO-- Lauren is an Associate Marriage and Family Therapist in San Francisco, California. She works with couples, individuals and people living with chronic illness. Lauren was diagnosed with Relapsing Multiple Sclerosis in 2015, and has found that although living with an autoimmune disease is not an easy path, it's brought more joy and fulfillment into her life than before. This January (2018) she launched the podcast "This is Not What I Ordered;" a weekly interview show about full-hearted living with chronic illness and health challenges. She believes that the biggest difficulties in our lives are often invitations into a deeper, richer, more conscious relationship with ourselves. HIGHLIGHTS-- Imago Couple's Dialogue Sender (no blaming, shaming or criticizing) Receiver mirrors word for word (provides summary and validating Validation--why it makes sense based on who the sender is (not based on the receiver) Two styles of conflict Minimizer Maximizer Both partners are needed to maintain the ecosystem (the balance in the relationship) Reflections to do weekly with your partner Something you did to support our relationship this week What was it like when you did that? Something I did this week to support the relationship How was it helpful to me If I could have a do-over this week, this is what I would do differently LINKS www.thisisnotwhatiordered.com www.laurenselfridgetherapy.com www.laurenselfridgephotography.com Twitter: @NWIOpodcast and @HelloSelfridge Instagram: @NWIOpodcast @LaurenSelfridgeOfficial Facebook: www.facebook.com/thisisnotwhatiordered Show hashtag: #NWIOpodcast Website-- www.patriciayounglcsw.com Podcast-- www.unapologeticallysensitive.com Facebook-- www.facebook.com/groups/2099705880047619/ Youtube-- www.youtube.com/channel/UCOE6foodj7RBdO3Iw0NrAllg/videos?view_as=subscriber Show hashtag-- #unapologeticallysensitive MUSIC--Gravel Dance by Andy Robinson www.andyrobinson.com e-mail-- unapologeticallysensitive!gmail.com    

In 2017, neuroimmunology experts revised the criteria with which we diagnose multiple sclerosis, they encouraged more aggressive treatment, and now they have introduced novel therapeutic agents into our pharmacologic armamentarium. Dr. Christopher Perrone explains how these newer agents work and how effective they are in patients with demyelinating disease. Produced by James E. Siegler. Music by Steve Combs, Pachyderm, and Lee Rosevere. BrainWaves' podcasts and online content are intended for medical education only and should not be used for clinical decision making. REFERENCES Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L, Opera I and Investigators OIC. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. The New England journal of medicine. 2017;376:221-234. Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, Bar-Or A, Panzara M, Sarkar N, Agarwal S, Langer-Gould A, Smith CH and Group HT. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. The New England journal of medicine. 2008;358:676-88. Hemmer B, Nessler S, Zhou D, Kieseier B and Hartung HP. Immunopathogenesis and immunotherapy of multiple sclerosis. Nat Clin Pract Neurol. 2006;2:201-11. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Rammohan KW, Selmaj K, Traboulsee A, Sauter A, Masterman D, Fontoura P, Belachew S, Garren H, Mairon N, Chin P, Wolinsky JS and Investigators OC. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. The New England journal of medicine. 2017;376:209-220. Selter RC and Hemmer B. Update on immunopathogenesis and immunotherapy in multiple sclerosis. Immunotargets Ther. 2013;2:21-30. Maloney DG, Grillo-Lopez AJ, White CA, Bodkin D, Schilder RJ, Neidhart JA, Janakiraman N, Foon KA, Liles TM, Dallaire BK, Wey K, Royston I, Davis T and Levy R. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90:2188-95.

Thursday's edition of Trending Today USA was hosted by Liftable Media's Ernie Brown.In this half hour, the guests and topics discussed were:1. The Top 5 Trending Stories2. Bob Ney (former congressman and member of the House Administration Committee) -- Federal police officials continue to investigate the Alexandria, Virginia shooting during a GOP baseball practice yesterday morning.3. Tom Hinchey (Liftable Media) -- A polygamous sect leader has been arrested after a year on the run.4. Jeff Howard (The Vegas Film Critic) -- Which movies coming out this week are worth seeing?5. Bryan Bickell (pro-ice hockey star) -- Bickell, who deals with Relapsing Multiple Sclerosis, applies some of the traits he used in hockey to fight the disease.Like us on Facebook!Image credit: Gage Skidmore/Flickr

Background: Multiple sclerosis (MS) is a chronic disease requiring long-term monitoring of treatment. Objective: To assess the four-year clinical efficacy of intramuscular (IM) IFNb-1a in patients with relapsing MS from the European IFNb-1a Dose-C omparison Study. Methods: Patients who completed 36 months of treatment (Part 1) of the European IFNb-1a Dose-C omparison Study were given the option to continue double-blind treatment with IFNb-1a 30 mcg or 60 mcg IM once weekly (Part 2). Analyses of 48-month data were performed on sustained disability progression, relapses, and neutralizing antibody (NA b) formation. Results: O f 608/802 subjects who completed 36 months of treatment, 493 subjects continued treatment and 446 completed 48 months of treatment and follow-up. IFNb-1a 30 mcg and 60 mcg IM once weekly were equally effective for up to 48 months. There were no significant differences between doses over 48 months on any of the clinical endpoints, including rate of disability progression, cumulative percentage of patients who progressed (48 and 43, respectively), and annual relapse rates; relapses tended to decrease over 48 months. The incidence of patients who were positive for NAbs at any time during the study was low in both treatment groups. Conclusion: C ompared with 60-mcg IM IFNb-1a once weekly, a dose of 30 mcg IM IFNb-1a once weekly maintains the same clinical efficacy over four years.